EyePoint Pharmaceuticals (STU:PV3B) Dividend Payout Ratio

: 0.00 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

EyePoint Pharmaceuticals's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for EyePoint Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:

STU:PV3B's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.415
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-16), the Dividend Yield % of EyePoint Pharmaceuticals is 0.00%.

EyePoint Pharmaceuticals's Dividends per Share for the months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

EyePoint Pharmaceuticals Dividend Payout Ratio Historical Data

The historical data trend for EyePoint Pharmaceuticals's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals Dividend Payout Ratio Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Dividend Payout Ratio falls into.

EyePoint Pharmaceuticals Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

EyePoint Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-1.644
	=	N/A

EyePoint Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.293
	=	N/A

EyePoint Pharmaceuticals (STU:PV3B) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

EyePoint Pharmaceuticals Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines